Findings

What do systematic reviews say?

227 questions · 258 findings · 32 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 68 · 26.4%GRADE not reported 32 · 12.4%Very low 47 · 18.2%Low 70 · 27.1%Moderate 34 · 13.2%High 7 · 2.7%

High‐dose vs low‐dose regimens of thrombolytic agents

Major bleeding · patients with < 42 days' limb ischaemiaa

1 finding from 1 review

Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 302 participants
Very low

High‐dose vs low‐dose regimens of thrombolytic agents

30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa

1 finding from 1 review

Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 302 participants
Very low

High‐dose vs low‐dose regimens of thrombolytic agents

Amputation · patients with < 42 days' limb ischaemiaa

1 finding from 1 review

Infusion techniques for peripheral arterial thrombolysis 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 302 participants
Very low

High‐dose vs low‐dose colchicine

Pain ‐ not reported · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout

High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
RR 0.87 [0.56, 1.36]
1 study · 126 participants
Low

High‐dose vs low‐dose colchicine

Reduction of inflammation ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Function of target joint ‐ not measured · acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose colchicine

Serious adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 126 participants
GRADE not reported

High‐dose vs low‐dose colchicine

Total adverse events · acute gout

High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
RR 2.11 [1.51, 2.95]
1 study · 126 participants
Low

High‐dose vs low‐dose colchicine

Withdrawals due to adverse events · acute gout

1 finding from 1 review

Colchicine for acute gout 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 126 participants
GRADE not reported

High‐dose vs low‐dose rFVIIa

Annualized joint Bleeding Rate (AjBR) · adults and children with hemophilia A or B with inhibitors

The review found no eligible studies for this question.

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose rFVIIa

Quality of life · adults and children with hemophilia A or B with inhibitors

The review found no eligible studies for this question.

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs low‐dose rFVIIa

Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 46 participants
Moderate

High‐dose vs low‐dose rFVIIa

Number of total bleeds per year or bleeding frequency · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

High‐dose vs low‐dose rFVIIa

Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
GRADE not reported

High‐dose vs low‐dose rFVIIa

Target joint bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Moderate

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Low

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

High‐dose vs low‐dose coenzyme Q10 and vitamin E

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported